Lupin Limited, a leading transnational pharmaceutical company, announced marked growth in its Environmental, Social, and Governance (ESG) performance, with its S&P Global ESG score now at 76, up from 69 last year. The gain positions Lupin far above the sector average of 30 for the pharma industry, reinforcing its commitment to sustainability and socially responsible business practices.
Lupin has been one of the fastest-rising names in the S&P Global ESG scores for the Indian pharmaceutical industry. The company has reflected steady and sustained growth in its ESG performance over the last four years, establishing it as a leader within the sector on the sustainability front. This is one of the reasons behind the success of the company. The sustainability framework has been integrated throughout the business activities of the company, including production and supply chain management, employee welfare, and social impact initiatives.
One of the core components of Lupin’s strategy is its expedited transition to net-zero emissions, which has been represented through the operational practice of the company. During the past year, Lupin has managed to increase its share of renewable energy usage up by 33.8%, a significant step towards drawing away from fossil fuels. The company has also reduced its carbon emission by 21% within the same period, symbolizing its commitment to curbing climate change and reducing its environmental footprint. Beside curbing emissions, Lupin has taken various steps forward to maintain water resources sustainably and attained the position of water positive for all the uses of water.
Lupin’s efforts towards sustainability in ESG are not limited to environmental impact alone. Rather, the company has emphasized social and governance factors equally. For example, Lupin realizes that, for success over the long run, a holistic approach to ESGs is prudent. The company has focused on the promotion of diversity, equity, and inclusion within its workforce-the work environment will be supportive of all in order to ensure that all employees are included. Lupin’s DEI initiatives have been critical in ensuring a culture of respect, equality, collaboration, and equal opportunity, and thus the company will be able to attract and retain diverse talent.
Lupin’s commitment towards employee wellbeing beyond diversity and inclusion is evident through the multiple programs designed for physical and mental well-being of employees. The company has provided resources toward stress management, a work-life balance, and general well-being for its employees. These initiatives have helped form a motivated and engaged workforce that is driving such sustainability and business goals for the company.
Ramesh Swaminathan, Executive Director, Global CFO, and Head of API Plus SBU at Lupin, shared his views on the company’s remarkable ESG achievements. According to him, “We have made significant progress in our Environmental, Social, and Governance goals over the last four years.”. The S&P score reaffirms our commitment to prioritizing sustainability and creating impactful and sustainable healthcare solutions that benefit our patients and our communities worldwide.” This statement highlights Lupin’s dedication to not only achieving ESG goals but also ensuring that these efforts translate into tangible benefits for society and the environment.
Lupin’s commitment to ESG principles extends to its supply chain as well. The company has actively worked to ensure that its suppliers share its sustainability values, promoting ethical sourcing, waste reduction, and environmental responsibility across its entire supply chain. This commitment is in line with the company’s broader goals of fostering a circular economy, where resources are reused and recycled, and waste is minimized.
In line with this, innovation at the heart of ESG forms the bedrock of the company’s focus. Lupin continues its patient-centric innovations, which translate to the development of products and solutions that meet the highest standards of quality and safety. The firm’s R&D efforts are dedicated to developing new and affordable therapies to address pressing health challenges faced by communities across the globe. This way, Lupin invests in innovative solutions for healthcare, making healthcare accessible and sustainable while fulfilling the needs of its customers around the world.
Concerning governance, Lupin has remained highly transparent and accountable. The company has put in place a strong system to track and report ESG results for actual performances and compliance with global acceptance standards and requirements of sustainability and regulations. Governance emphasizes ethical conduct, integrity, and responsible decision-making from the lowest to the highest-ranking members of the organization.
Although Lupin maintains a holistic approach to sustainability, it has received recognition as one of the best performing companies in ESG performance in India’s pharmaceutical sector. The company has an excellent commitment to sustainability, achieving outstanding ESG scores and improving its position as a responsible corporate entity focused on long-term value creation for all stakeholders.
Looking forward, Lupin remains committed to its progression in every aspect of ESG. It intends to further the reduction of its impacts on the environment, enhance its social initiatives, and maintain high standards of governance. The company is also looking at new areas of innovation in sustainable healthcare as it addresses the emerging global health issues across the globe with continuous commitment to environment stewardship.
Lupin’s journey is an excellent example of how a pharmaceuticals company can consolidate ESG principles within the operations of the organization, driving both business growth and social and environmental impact. As the organisation continues to improve in its ESG performance, it is very aptly placed for leadership in ushering in a more sustainable and equitable future, not just in India but globally.